SARS-CoV-2(2019-nCoV)
ELISA, Neutralization
Human
IgM
S309
Human betacoronavirus 2c EMC/2012
FCM, Neutralization, SPR
Human
IgG1, kappa
2E6#
SARS-CoV-2
Neutralization
Human
IgG1, kappa
1H1
SARS-CoV-2
Neutralization
Human
IgG1, kappa
5E1#
Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2)
Neutralization
Human
IgG1, kappa
S2P6
SARS-CoV-2(2019-nCoV), SARS-CoV
ELISA, Neutralization
Human
IgG1, kappa
S309
Middle East respiratory syndrome-related coronavirus (isolate United Kingdom/H123990006/2012) (MERS-CoV) (Betacoronavirus England 1)
Neutralization
Human
IgG1, kappa
S41
Middle East respiratory syndrome-related coronavirus (isolate UnitedKingdom/H123990006/2012) (MERS-CoV) (Betacoronavirus England 1)
ELISA, Neutralization
Human
IgG1, kappa
D12
Human betacoronavirus 2c EMC/2012
ELISA, Neutralization
Human
IgG1, kappa
4C2
SARS-CoV-2
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Human
IgG1-kappa
VIR-7229